Concord Drugs gets nod to acquire entire stake in Proton Remedies

08 Sep 2022 Evaluate

Concord Drugs has received approval to acquire upto 100% stake in Proton Remedies (PRPL) at a consideration of Rs 283 per share on cash basis. The main objective of acquisition is to gain access of existing marketing network of PRPL to sell the products of Concord Drugs. The board of directors at its meeting held on September 07, 2022 has approved the same.

Concord Drugs is engaged in developing new products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery.

Concord Drugs Share Price

76.77 2.52 (3.39%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×